Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers

  • Aman Kumar
  • Niti Kumari
  • Nayudu Nallabelli
  • Rajendra PrasadEmail author
Review Article


Histone modifications occupy an essential position in the epigenetic landscape of the cell, and their alterations have been linked to cancers. Histone 3 lysine 4 (H3K4) methylation has emerged as a critical epigenetic cue for the regulation of gene transcription through dynamic modulation by several H3K4 methyltransferases (writers) and demethylases (erasers). Any disturbance in the delicate balance of writers and erasers can result in the mis-regulation of H3K4 methylation, which has been demonstrated in several human cancers. Therefore, H3K4 methylation has been recognized as a putative therapeutic or prognostic tool and drug trials of different inhibitors of this process have demonstrated promising results. Henceforth, more detailed knowledge of H3K4 methylation is utmost important for elucidating the complex cellular processes, which might help in improving the disease outcome. The primary focus of this review will be directed on deciphering the role of H3K4 methylation along with its writers/erasers in different cancers.


H3K4 methylation Histone methyltransferases Histone demethylases Prognosis Therapeutics Cancer 


Author’s Contribution

All authors are involved in the design, preparation of manuscript, read and final approval of the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors have no conflict of interest.

Ethical Approval

This is a review article and does not involve experiments with human subjects or animals performed by any of the authors.


  1. 1.
    Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetic. Genes Dev. 2009;23:781–3.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Crea F. Histone code, human growth and cancer. Oncotarget. 2012;3:1–2.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Biancotto C, Frigè G, Minucci S. Histone modification therapy of cancer. Adv Genet. 2010;70:341–86.CrossRefPubMedGoogle Scholar
  4. 4.
    Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.CrossRefPubMedGoogle Scholar
  5. 5.
    Bowman GD, Poirier MG. Post-translational modifications of histones that influence nucleosome dynamics. Chem Rev. 2015;115:2274–95.CrossRefPubMedGoogle Scholar
  6. 6.
    Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–80.CrossRefPubMedGoogle Scholar
  7. 7.
    Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343–57.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ng SS, Yue WW, Oppermann U, Klose RJ. Dynamic protein methylation in chromatin biology. Cell Mol Life Sci. 2009;66:407–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucl Acid Res Mol Biol. 1998;61:65–131.CrossRefGoogle Scholar
  10. 10.
    Chervona Y, Costa M. Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res. 2012;2:589–97.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Barski S, Cuddapah K, Cui TY, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823–37.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhang X, Huang Y, Shi X. Emerging roles of lysine methylation on non-histone proteins. Cell Mol Life Sci. 2015;72:4257–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Kampranis SC, Tsichlis PN. Histone demethylases and cancer. Adv Cancer Res. 2009;102:103–69.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Keppler BR, Archer TK. Chromatin-modifying enzymes as therapeutic targets—part 1. Expert Opin Ther Targets. 2008;12:1301–12.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002;111:105–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Mohan M, Herz HM, Smith ER, Zhang Y, Jackson J, Washburn MP, et al. The COMPASS family of H3K4 methylases in Drosophila. Mol Cell Biol. 2011;31:4310–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 2012;81:65–95.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhang X, Wen H, Shi X. Lysine methylation: beyond histones. Acta Biochim Biophys Sin. 2012;44:14–27.CrossRefPubMedGoogle Scholar
  19. 19.
    Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53.CrossRefPubMedGoogle Scholar
  20. 20.
    Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11:384–400.CrossRefPubMedGoogle Scholar
  21. 21.
    Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, et al. A novel mammalian flavin dependent histone demethylase. J Biol Chem. 2009;284:17775–82.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochem Biophys Acta. 2011;1815:75–89.PubMedGoogle Scholar
  23. 23.
    Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49:e324.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439:811–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Ali M, Hom RA, Blakeslee W, Ikenouye L, Kutateladze TG. Diverse functions of PHD fingers of the MLL/KMT2 subfamily. Biochim Biophys Acta. 2014;1843:366–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407–12.CrossRefPubMedGoogle Scholar
  27. 27.
    Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, et al. Global histone modifications predict prognosis of resected non-small-cell lung cancer. J Clin Oncol. 2007;25:4358–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009;69:3802–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol. 2010;28:1358–65.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010;70:61–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomark Prev. 2010;19:2611–22.CrossRefGoogle Scholar
  34. 34.
    Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer. 2010;127:2360–6.CrossRefPubMedGoogle Scholar
  35. 35.
    He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012;43:1425–35.CrossRefPubMedGoogle Scholar
  36. 36.
    Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med. 2004;10:500–7.CrossRefPubMedGoogle Scholar
  37. 37.
    So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 2003;4:99–110.CrossRefPubMedGoogle Scholar
  38. 38.
    Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20:5695–707.CrossRefPubMedGoogle Scholar
  39. 39.
    Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007;67:3545–50.CrossRefPubMedGoogle Scholar
  40. 40.
    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hamamoto R, Nakamura Y. Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Sci. 2016;107:377–84.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Salz T, Li G, Kaye F, Zhou L, Qiu Y, Huang S. hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. Cancer Res. 2014;74:775–86.CrossRefPubMedGoogle Scholar
  43. 43.
    Kumar A, Kumari N, Rai A, Singh SK, Kakkar N, Prasad R. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma. Gene. 2018;674:31–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Li J, Yin C, Okamoto H, Mushlin H, Balgley BM, Lee CS, et al. Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol. 2008;10:45–51.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    He C, Liu C, Wang L, Sun Y, Jiang Y, Hao Y. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma. Cell Death Dis. 2019;10:65.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics. 2001;74:79–88.CrossRefPubMedGoogle Scholar
  47. 47.
    Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, et al. Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS ONE. 2014;9:e98293.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA. 2005;102:9625–30.CrossRefPubMedGoogle Scholar
  49. 49.
    Coda DM, Lingua MF, Morena D, Foglizzo V, Bersani F, Ala U, et al. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. Cell Cycle. 2015;14:1389–402.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–40.CrossRefPubMedGoogle Scholar
  51. 51.
    Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009;30:1139–46.CrossRefPubMedGoogle Scholar
  53. 53.
    Reynoird N, Mazur PK, Stellfeld T, Flores NM, Lofgren SM, Carlson SM, et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 2016;30:772–85.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Li B, Pan R, Zhou C, Dai J, Mao Y, Chen M, et al. SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer. Future Oncol. 2018;14:1825–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Fei X, Ma Y, Liu X, Meng Z. Overexpression of SMYD3 is predictive of unfavorable prognosis in hepatocellular carcinoma. Tohoku J Exp Med. 2017;243:219–26.CrossRefPubMedGoogle Scholar
  56. 56.
    Lobo J, Rodrigues Â, Antunes L, Graça I, Ramalho-Carvalho J, Vieira FQ, et al. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urol Oncol. 2018;36:161.e7–17.CrossRefGoogle Scholar
  57. 57.
    Zuo SR, Zuo XC, He Y, Fang WJ, Wang CJ, Zou H, et al. Positive expression of SMYD2 is associated with poor prognosis in patients with primary hepatocellular carcinoma. J Cancer. 2018;9:321–30.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Xu W, Chen F, Fei X, Yang X, Lu X. Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with tumor progression and poor prognosis in patients with papillary thyroid carcinoma. Med Sci Monit. 2018;24:7357–65.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, et al. LSD1 demethylates repressive histone marks to promote androgenreceptor-dependent transcription. Nature. 2005;437:436–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437:432–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008;319:202–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, et al. Lysine-specic demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010;31:512–20.CrossRefPubMedGoogle Scholar
  63. 63.
    Lee MG, Wynder C, Bochar DA, Hakimi MA, Cooch N, Shiekhattar R, et al. Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol. 2006;26:6395–402.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66:11341–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Lee C, Rudneva VA, Erkek S, Zapatka M, Chau LQ, Tacheva-Grigorova SK, et al. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. Nat Commun. 2019;10:332.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Nagasaka M, Tsuzuki K, Ozeki Y, Tokugawa M, Ohoka N, Inoue Y, et al. Lysine-specific demethylase 1 (LSD1/KDM1A) is a novel target gene of c-Myc. Biol Pharm Bull. 2019;42:481–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Wang Y, Sun L, Luo Y, He S. Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells. Pathol Res Pract 2019 [Epub ahead of print].Google Scholar
  68. 68.
    Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res Treat. 2014;146:99–108.CrossRefPubMedGoogle Scholar
  69. 69.
    Cao Y, Guo C, Yin Y, Li X, Zhou L. Lysine-specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI-2. Mol Med Rep. 2018;18:733–40.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest. 2013;123:727–39.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Zhao E, Tang C, Jiang X, Weng X, Zhong X, Zhang D. Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells. Cell Signal. 2017;36:222–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Zeng J, Ge Z, Wang L, Li Q, Wang N, Björkholm M, et al. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology. 2010;138:981–92.CrossRefPubMedGoogle Scholar
  73. 73.
    Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Zhou D, Kannappan V, Chen X, Li J, Leng X, Zhang J, et al. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Exp Mol Med. 2016;48:e238.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, Scibetta AG, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer. 2002;101:581–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA. 2007;104:19226–31.CrossRefPubMedGoogle Scholar
  77. 77.
    Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25:801–12.CrossRefPubMedGoogle Scholar
  78. 78.
    Kuo KT, Huang WC, Bamodu OA, Lee WH, Wang CH, Hsiao M, et al. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. Clin Epigenet. 2018;10:107.CrossRefGoogle Scholar
  79. 79.
    Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, et al. Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget. 2018;9:34320–35.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Li L, Shou H, Wang Q, Liu S. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma. Gene. 2019;694:76–82.CrossRefPubMedGoogle Scholar
  81. 81.
    Xiao PF, Tao YF, Hu SY, Cao L, Lu J, Wang J, et al. mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia. Pharmazie. 2017;72:177–86.PubMedGoogle Scholar
  82. 82.
    Lin H, Yang G, Yu J, Wang J, Li Q, Guo S, et al. KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1. Biomed Pharmacother. 2018;107:1205–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Kumar A, Kumari N, Gupta V, Prasad R. Renal cell carcinoma: molecular aspects. Indian J Clin Biochem. 2018;33:246–54.CrossRefPubMedGoogle Scholar
  84. 84.
    Rondinelli B, Rosano D, Antonini E, Frenquelli M, Montanini L, Huang D, et al. Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer. J Clin Invest. 2015;125:4625–37.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci USA. 2016;113:6259–64.CrossRefPubMedGoogle Scholar
  86. 86.
    Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, et al. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 2016;76:831–43.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Zhang L, Wang T, Geng BS, Ren K. Histone modifications as therapeutic targets for cancer. UK J Pharm Biosci. 2014;2:01–4.CrossRefGoogle Scholar
  88. 88.
    McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther. 2015;150:1–22.CrossRefPubMedGoogle Scholar
  89. 89.
    Singh MM, Johnson B, Venkatarayan A, Flores ER, Zhang J, Su X, et al. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol. 2015;17:1463–73.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life. 2010;62:194–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Hashimoto T, Yamakawa M, Kimura S, Usuba O, Toyono M. Expression of acetylated and dimethylated histone H3 in colorectal cancer. Dig Surg. 2013;30:249–58.CrossRefPubMedGoogle Scholar
  92. 92.
    Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S, et al. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. EJSO. 2013;39:655–61.CrossRefPubMedGoogle Scholar
  93. 93.
    Benard A, Goossens-Beumer IJ, Van-Hoesel AQ, de Graaf W, Horati H, Putter H, et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early stage colon cancer. BMC Cancer. 2014;14:531.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, et al. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int. 2011;108:290–6.CrossRefGoogle Scholar
  95. 95.
    Canaani E, Nakamura T, Rozovskaia T, Smith ST, Mori T, Croce CM, et al. ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia. Br J Cancer. 2004;90:756–60.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Zhu Q, Fang L, Heuberger J, Kranz A, Schipper J, Scheckenbach K, et al. The Wnt-Driven Mll1 epigenome regulates salivary gland and head and neck cancer. Cell Rep. 2019;26:415–28.CrossRefPubMedGoogle Scholar
  97. 97.
    Ge S, Li B, Li Y, Li Z, Liu Z, Chen Z, et al. Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing. Am J Cancer Res. 2017;7:1540–53.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Lu H, Yang S, Zhu H, Tong X, Xie F, Qin J, et al. Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma. BMC Cancer. 2018;18:251.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Yang B, Li J, Li F, Zhou H, Shi W, Shi H, et al. Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients. Cancer Med 2019 [Epub ahead of print].Google Scholar
  100. 100.
    Wang XX, Fu L, Li X, Wu X, Zhu Z, Fu L, et al. Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res. 2011;17:429–33.CrossRefPubMedGoogle Scholar
  101. 101.
    Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, et al. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Rep 2019; 20:e46821.Google Scholar
  102. 102.
    Cho SJ, Yoon C, Lee JH, Chang KK, Lin JX, Kim YH, et al. KMT2C mutations in diffuse-type gastric adenocarcinoma promote epithelial-to-mesenchymal transition. Clin Cancer Res. 2018;24:6556–69.CrossRefPubMedGoogle Scholar
  103. 103.
    Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 2013;4:2144–53.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Koutsioumpa M, Hatziapostolou M, Polytarchou C, Tolosa EJ, Almada LL, Mahurkar-Joshi S, et al. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming. Gut 2018 [Epub ahead of print].Google Scholar
  105. 105.
    Xiong W, Deng Z, Tang Y, Deng Z, Li M. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer. Biochem Biophys Res Commun. 2018;504:129–36.CrossRefPubMedGoogle Scholar
  106. 106.
    Deng LW, Chiu I, Strominger JL. MLL5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc Natl Acad Sci. 2004;101:757–62.CrossRefPubMedGoogle Scholar
  107. 107.
    Je EM, Lee SH, Yoo NJ, Lee SH. Mutational and expressional analysis of MLL genes in gastric and colorectal cancers with microsatellite instability. Neoplasma. 2013;60:188–95.CrossRefPubMedGoogle Scholar
  108. 108.
    Rabello Ddo A, de Moura CA, de Andrade RV, Motoyama AB, Silva FP. Altered expression of MLL methyltransferase family genes in breast cancer. Int J Oncol. 2013;43:653–60.CrossRefPubMedGoogle Scholar
  109. 109.
    Choi YJ, Oh HR, Choi MR, Gwak M, An CH, Chung YJ, et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol. 2014;45:1674–81.CrossRefPubMedGoogle Scholar
  110. 110.
    Qi J, Huo L, Zhu YT, Zhu YJ. Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3). J Biol Chem. 2014;289:31373–81.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Peveling-Oberhag J, Wolters F, Döring C, Walter D, Sellmann L, Scholtysik R, et al. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. BMC Cancer. 2015;15:773.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Li LX, Zhou JX, Calvet JP, Godwin AK, Jensen RA, Li X. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis. 2018;9:326.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    García-Carpizo V, Sarmentero J, Han B, Graña O, Ruiz-Llorente S, Pisano DG, et al. SD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Sci Rep. 2016;8(6):32952.CrossRefGoogle Scholar
  114. 114.
    Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, et al. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene. 2019;38:671–86.CrossRefPubMedGoogle Scholar
  115. 115.
    Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, et al. The histone methyltransferase Wolf–Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer. 2013;52:126–39.CrossRefPubMedGoogle Scholar
  116. 116.
    Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Höller T, et al. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol. 2010;41:181–9.CrossRefPubMedGoogle Scholar
  117. 117.
    Fukuda T, Tokunaga A, Sakamoto R, Yoshida N. Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. Mol Cell Neurosci. 2011;46:614–24.CrossRefPubMedGoogle Scholar
  118. 118.
    Ham J, Lee S, Lee H, Jeong D, Park S, Kim SJ. Genome-wide methylation analysis identifies NOX4 and KDM5A as key regulators in inhibiting breast cancer cell proliferation by ginsenoside Rg3. Am J Chin Med. 2018;46:1333–55.CrossRefPubMedGoogle Scholar
  119. 119.
    Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol. 2000;163:1339–42.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2019

Authors and Affiliations

  1. 1.Department of BiochemistryPostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  2. 2.Department of EndocrinologyPostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations